The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Adult Generalized Anxiety Disorder: Ketamine Augmentation Therapy

Emerging glutamatergic intervention for treatment-resistant generalized anxiety with monitored protocols

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Psikiyatri department. Book Appointment →

What is Adult Generalized Anxiety Disorder: Ketamine Augmentation Therapy?

Ketamine acts on N-methyl-D-aspartate (NMDA) receptors and downstream glutamatergic signaling, producing rapid antidepressant and anxiolytic effects distinct from traditional therapies.

Subanesthetic doses delivered intravenously, intramuscularly, intranasally (esketamine) or sublingually have been studied for refractory anxiety conditions.

Emerging evidence supports use in treatment-resistant generalized anxiety disorder where standard SSRI, SNRI and benzodiazepine approaches have failed.

Mechanism includes NMDA receptor antagonism, AMPA receptor activation, BDNF release and rapid synaptogenesis in prefrontal cortex.

Treatment requires specialized clinic settings with cardiovascular monitoring, dissociation assessment and integration with ongoing psychiatric care.

Symptoms

Persistent excessive worry, restlessness, fatigue, concentration difficulty and sleep disturbance for more than 6 months.
Functional impairment in occupational, social or family domains despite adequate trials of standard pharmacotherapy.
Treatment resistance defined as inadequate response to at least two trials of evidence-based anxiety medications at adequate doses and duration.
Significant comorbidity with depression where ketamine evidence is more robust may also predict response.
Patient preference and shared decision-making consideration for novel treatment options.

Risk Factors

Cardiovascular disease including uncontrolled hypertension, recent myocardial infarction or cerebrovascular accident is a relative contraindication.
Active psychosis or history of psychotic disorder requires careful evaluation and consideration.
Active substance use disorder particularly involving stimulants or hallucinogens warrants caution.
Pregnancy or breastfeeding due to limited safety data.
Patient inability to comply with monitoring requirements or absence of adequate support system.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent severe anxiety despite adequate trials of standard pharmacotherapy and psychotherapy warrants psychiatric reassessment.
  • Significant functional impairment from anxiety symptoms requires comprehensive treatment planning and consideration of advanced interventions.
  • Suicidal ideation or behavior in context of severe anxiety needs urgent psychiatric evaluation.
  • Interest in exploring novel treatment options including ketamine merits consultation with specialized psychiatrist.
  • Long-term medication management with regular follow-up and reassessment is essential for durable outcomes.

Treatment Methods

01
Comprehensive psychiatric evaluation establishing treatment resistance and excluding contraindications precedes ketamine consideration.
02
Induction phase typically involves multiple sessions over 2 to 4 weeks at specialized clinic with cardiovascular and dissociation monitoring.
03
Maintenance treatment with periodic boosters tailored to individual response and durability.
04
Concurrent evidence-based therapy with cognitive behavioral therapy, mindfulness-based stress reduction or acceptance and commitment therapy.
05
Comprehensive care coordination, monitoring for adverse effects including dissociation, hypertension and bladder symptoms, lifestyle optimization and management of comorbidities including depression and sleep disturbance optimize outcomes in this emerging treatment paradigm.

Which Department to Visit?

You can visit our Psikiyatri department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Psikiyatri Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.